51
Articles Count
32984
Viewing Count
Minhua Chu

Dean of Research Institute

2021 wraps up with multi-billion dollar deals
Minhua Chu · 15 days ago
In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
Further information
China Deals Tracker
China regulates clinical use of innovative oncolog...
Minhua Chu · 16 days ago
The new guidelines clarify that some drugs need biomarker testing before prescriptions and listed specific biomarker requirements and recommendations for each drug.
Further information
Regulatory
Henlius plans for approval of its PD-1 lung cancer...
Minhua Chu · 18 days ago
Shanghai Henlius Biotech is beginning to see strong sales from its trastuzumab biosimilar and wants to take its PD-1 drug abroad.
Further information
Feature
China’s NRDL explained: 67 new drugs, 62% price c...
Minhua Chu · 1 months ago
The Dec. 10 update of the list included 67 branded drugs with no generic versions for the first time. On average, prices were cut by 61.7% — the biggest since 2017.
Further information
Feature
API manufacturers targeted by China’s new anti-mo...
Minhua Chu · 1 months ago
Shortly after the government of China launched its anti-monopoly bureau, an active pharmaceutical ingredient (API) manufacturer from Nanjing was fined RMB6.58 million ($1 million) for abusing its dominant market position and inflating prices. The swift action has sent a chill down API manufacturers’ spines.
Further information
Regulatory
Hansoh’s siRNA therapeutics deals stand out in Oc...
Minhua Chu · 2 months ago
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
Further information
China Deals Tracker
China issues guidelines for developing orphan drug...
Minhua Chu · 2 months ago
China’s CDE released its first technical guidelines for the clinical development of orphan drugs, demonstrating a concrete step by Beijing towards tackling rare diseases.
Further information
Regulatory
September sees the most licensing deals of the yea...
Minhua Chu · 2 months ago
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.
Further information
China Deals Tracker
Exclusive: Former FDA official calls Aduhelm appro...
Minhua Chu · 3 months ago
Why was the approval decision so controversial? Has the FDA lowered its normal standards during the review? Wang clarified the questions about the review with data from the published FDA reports.
Further information
Feature
Chinese cancer drugmakers win more approvals than ...
Minhua Chu · 3 months ago
For the first time, Chinese drugmakers have won more approvals for cancer drugs than their foreign peers, but drug development is too concentrated in oncology and certain targets, regulators said at two recent conferences.
Further information
Regulatory
READ MORE

Personal Information

Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement